TrialClinical cancer research : an official journal of the American Association for Cancer Research2019

Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.

Gary A Ulaner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.